Skip to content

Epoprostenol

Flolan, Veletri (epoprostenol) is a small molecule pharmaceutical. Epoprostenol was first approved as Flolan on 1995-09-20. It is used to treat arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, and respiratory distress syndrome amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype. In addition, it is known to target prostaglandin E2 receptor EP4 subtype and prostacyclin receptor. Flolan's patent is valid until 2027-03-15 (FDA).
Trade Name Flolan, Veletri
Common Name Epoprostenol
Indication arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, respiratory distress syndrome, systemic scleroderma
Drug Class Prostaglandins
Epoprostenol
Get full access now